411 related articles for article (PubMed ID: 32410680)
1. Hepatic steatosis induced in C57BL/6 mice by a non-ß oxidizable fatty acid analogue is associated with reduced plasma kynurenine metabolites and a modified hepatic NAD
Berge RK; Cacabelos D; Señarís R; Nordrehaug JE; Nygård O; Skorve J; Bjørndal B
Lipids Health Dis; 2020 May; 19(1):94. PubMed ID: 32410680
[TBL] [Abstract][Full Text] [Related]
2. Increased fatty acid oxidation and mitochondrial proliferation in liver are associated with increased plasma kynurenine metabolites and nicotinamide levels in normolipidemic and carnitine-depleted rats.
Lindquist C; Bjørndal B; Lund A; Slettom G; Skorve J; Nygård O; Svardal A; Berge RK
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Feb; 1865(2):158543. PubMed ID: 31676443
[TBL] [Abstract][Full Text] [Related]
3. Tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice.
Berge RK; Bjørndal B; Strand E; Bohov P; Lindquist C; Nordrehaug JE; Svardal A; Skorve J; Nygård O
Lipids Health Dis; 2016 Feb; 15():24. PubMed ID: 26846427
[TBL] [Abstract][Full Text] [Related]
4. Insulin resistance and dysregulation of tryptophan-kynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways.
Oxenkrug G
Mol Neurobiol; 2013 Oct; 48(2):294-301. PubMed ID: 23813101
[TBL] [Abstract][Full Text] [Related]
5. Hepatic NAD
Dall M; Penke M; Sulek K; Matz-Soja M; Holst B; Garten A; Kiess W; Treebak JT
Mol Cell Endocrinol; 2018 Sep; 473():245-256. PubMed ID: 29408602
[TBL] [Abstract][Full Text] [Related]
6. Hepatic fatty acid metabolism as a determinant of plasma and liver triacylglycerol levels. Studies on tetradecylthioacetic and tetradecylthiopropionic acids.
Asiedu DK; al-Shurbaji A; Rustan AC; Björkhem I; Berglund L; Berge RK
Eur J Biochem; 1995 Feb; 227(3):715-22. PubMed ID: 7867630
[TBL] [Abstract][Full Text] [Related]
7. Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing.
Zhou CC; Yang X; Hua X; Liu J; Fan MB; Li GQ; Song J; Xu TY; Li ZY; Guan YF; Wang P; Miao CY
Br J Pharmacol; 2016 Aug; 173(15):2352-68. PubMed ID: 27174364
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Rewiring of Kynurenine Pathway during Hepatic Ischemia-Reperfusion Injury Exacerbates Liver Damage by Impairing NAD Homeostasis.
Xu B; Zhang P; Tang X; Wang S; Shen J; Zheng Y; Gao C; Mi P; Zhang C; Qu H; Li S; Yuan D
Adv Sci (Weinh); 2022 Dec; 9(35):e2204697. PubMed ID: 36310151
[TBL] [Abstract][Full Text] [Related]
9. A mouse model of the regression of alcoholic hepatitis: Monitoring the regression of hepatic steatosis, inflammation, oxidative stress, and NAD
Kang H; Kim MB; Park YK; Lee JY
J Nutr Biochem; 2022 Jan; 99():108852. PubMed ID: 34525389
[TBL] [Abstract][Full Text] [Related]
10. Kynurenine pathway, NAD
Castro-Portuguez R; Sutphin GL
Exp Gerontol; 2020 Apr; 132():110841. PubMed ID: 31954874
[TBL] [Abstract][Full Text] [Related]
11. Metabolomic analysis shows dysregulation in amino acid and NAD+ metabolism in palmitate treated hepatocytes and plasma of non-alcoholic fatty liver disease spectrum.
Aggarwal S; Yadav V; Maiwall R; Rastogi A; Pamecha V; Bedi O; Maras JS; Trehanpati N; Ramakrishna G
Biochem Biophys Res Commun; 2023 Feb; 643():129-138. PubMed ID: 36603530
[TBL] [Abstract][Full Text] [Related]
12. Quinolinate as a Marker for Kynurenine Metabolite Formation and the Unresolved Question of NAD
Moffett JR; Arun P; Puthillathu N; Vengilote R; Ives JA; Badawy AA; Namboodiri AM
Front Immunol; 2020; 11():31. PubMed ID: 32153556
[TBL] [Abstract][Full Text] [Related]
13. Deficiency of the Mitochondrial NAD Kinase Causes Stress-Induced Hepatic Steatosis in Mice.
Zhang K; Kim H; Fu Z; Qiu Y; Yang Z; Wang J; Zhang D; Tong X; Yin L; Li J; Wu J; Qi NR; Houten SM; Zhang R
Gastroenterology; 2018 Jan; 154(1):224-237. PubMed ID: 28923496
[TBL] [Abstract][Full Text] [Related]
14. The kynurenine pathway activities in a sub-Saharan HIV/AIDS population.
Bipath P; Levay PF; Viljoen M
BMC Infect Dis; 2015 Aug; 15():346. PubMed ID: 26285873
[TBL] [Abstract][Full Text] [Related]
15. Sleeve gastrectomy ameliorated high-fat diet (HFD)-induced non-alcoholic fatty liver disease and upregulated the nicotinamide adenine dinucleotide +/ Sirtuin-1 pathway in mice.
Hua R; Wang GZ; Shen QW; Yang YP; Wang M; Wu M; Shao YK; He M; Zang Y; Yao QY; Zhang ZY
Asian J Surg; 2021 Jan; 44(1):213-220. PubMed ID: 32712045
[TBL] [Abstract][Full Text] [Related]
16. Supplementation with a Specific Combination of Metabolic Cofactors Ameliorates Non-Alcoholic Fatty Liver Disease, Hepatic Fibrosis, and Insulin Resistance in Mice.
Quesada-Vázquez S; Colom-Pellicer M; Navarro-Masip È; Aragonès G; Del Bas JM; Caimari A; Escoté X
Nutrients; 2021 Oct; 13(10):. PubMed ID: 34684533
[TBL] [Abstract][Full Text] [Related]
17. Associations between fatty acid oxidation, hepatic mitochondrial function, and plasma acylcarnitine levels in mice.
Bjørndal B; Alterås EK; Lindquist C; Svardal A; Skorve J; Berge RK
Nutr Metab (Lond); 2018; 15():10. PubMed ID: 29422939
[TBL] [Abstract][Full Text] [Related]
18. Nicotinamide riboside, an NAD+ precursor, attenuates the development of liver fibrosis in a diet-induced mouse model of liver fibrosis.
Pham TX; Bae M; Kim MB; Lee Y; Hu S; Kang H; Park YK; Lee JY
Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2451-2463. PubMed ID: 31195117
[TBL] [Abstract][Full Text] [Related]
19. NAD
Li DJ; Sun SJ; Fu JT; Ouyang SX; Zhao QJ; Su L; Ji QX; Sun DY; Zhu JH; Zhang GY; Ma JW; Lan XT; Zhao Y; Tong J; Li GQ; Shen FM; Wang P
Theranostics; 2021; 11(9):4381-4402. PubMed ID: 33754067
[No Abstract] [Full Text] [Related]
20. Nicotinamide prevents sweet beverage-induced hepatic steatosis in rats by regulating the G6PD, NADPH/NADP
Mejía SÁ; Gutman LAB; Camarillo CO; Navarro RM; Becerra MCS; Santana LD; Cruz M; Pérez EH; Flores MD
Eur J Pharmacol; 2018 Jan; 818():499-507. PubMed ID: 29069580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
